FDMT — 4D Molecular Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$14.33
-$0.02 (-0.14%)
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on NASDAQ. It is led by David H. Kirn M.D., based in 5858 Horton Street, EmeryVille, CA, United States, 94608, with about 196 employees. 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Latest reported FDMT revenue for 2025-09-30 was $90.0K. Net income was -$159.5M. Revenue was up 500.0% from 2025-06-30 to 2025-09-30. FDMT currently screens at market cap $518.1M.
Use this FDMT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FDMT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FDMT SEC filings page. Lician reads the product cache first so this HTML stays unique to 4D Molecular Therapeutics Inc even when a live quote feed is slow.
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
FDMT Key Statistics
Market Cap
$518.06M
Volume
852,700
Previous Close
$15.39
Day Range
$15.41 – $16.34
EPS
-$2.98
Revenue
$37.00K
Net Income
-$160.87M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-99.8%
Profit Margin
-434778.4%
Employees
196
FDMT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $37.00K | $20.72M | $3.13M | $18.04M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$160.87M | -$100.84M | -$107.49M | -$71.32M |
| EPS (Diluted) | -$2.98 | -$2.58 | -$3.32 | -$2.57 |
Total Assets
$560.38M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$149.34M
Operating Cash Flow
-$134.59M
Free Cash Flow
$0.00
4D Molecular Therapeutics Inc Company Information
- Co-Founder, President, CEO & Director
- David H. Kirn M.D.
- Headquarters
- 5858 Horton Street, EmeryVille, CA, United States, 94608
- Phone
- 510 505 2680
- IPO / Founded
- 2020-12-11
- Sector
- Healthcare
- Industry
- Biotechnology